A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive diseasePaola Papaldo, F. Cognetti, Anna Maria Cianciulli et al.|Annals of Oncology|2006Cited by 82
Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.Alessandra Fabi, F. Cognetti, Paola Papaldo et al.|PubMed|2004Cited by 8